Companies sponsors |
Sanofi |
Others |
Department of Health and Social Care |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Blood Cancer UK |
|
Myeloma UK |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Physicians |
|
Royal College of Radiologists |
|
UK Myeloma Society |
Associated public health groups |
None |
Comparator companies |
Advanz Pharma (dexamethasone, lenalidomide) confidentiality agreement not signed, not participating |
|
Aspen (dexamethasone) confidentiality agreement not signed, not participating |
|
Aspire Pharma (dexamethasone) confidentiality agreement not signed, not participating |
|
Bristol Myers Squibb (lenalidomide, pomalidomide) confidentiality agreement not signed, not participating |
|
Cipla (lenalidomide) confidentiality agreement not signed, not participating |
|
GlaxoSmithKline (belantamab mafodotin) confidentiality agreement not signed, not participating |
|
Glenmark Pharmaceuticals (dexamethasone) confidentiality agreement not signed, not participating |
|
hameln pharma (dexamethasone) confidentiality agreement not signed, not participating |
|
Hospira (dexamethasone) confidentiality agreement not signed, not participating |
|
Janssen-Cilag (ciltacabtagene autoleucel, daratumumab) confidentiality agreement not signed, not participating |
|
Laboratoires CTRS (dexamethasone) – confidentiality agreement not signed, not participating |
|
Martindale Pharma (dexamethasone) – confidentiality agreement not signed, not participating |
|
Mylan (lenalidomide) – confidentiality agreement not signed, not participating |
|
Noridem Enterprises (dexamethasone) – confidentiality agreement not signed, not participating |
|
Panpharma (dexamethasone) – confidentiality agreement not signed, not participating |
|
Pfizer (elranatamab) – confidentiality agreement not signed, not participating |
|
Piramal Critical Care (lenalidomide) – confidentiality agreement not signed, not participating |
|
Ranbaxy (lenalidomide) – confidentiality agreement not signed, not participating |
|
Rosemont Pharmaceuticals (dexamethasone) – confidentiality agreement not signed, not participating |
|
Sandoz (lenalidomide) – confidentiality agreement not signed, not participating |
|
Synchrony Pharma (dexamethasone) – confidentiality agreement not signed, not participating |
|
Takeda (ixazomib) – confidentiality agreement not signed, not participating |
|
Teva (lenalidomide) – confidentiality agreement not signed, not participating |
|
Thame Laboratories (dexamethasone) – confidentiality agreement not signed, not participating |
|
Thornton & Ross (lenalidomide) – confidentiality agreement not signed, not participating |
|
Wockhardt (dexamethasone) – confidentiality agreement not signed, not participating |
|
Zentiva (lenalidomide) – confidentiality agreement not signed, not participating |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Health Technology Wales (HTW) |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |
|
National Institute for Health Research |